
TSE:ZUH
This summary was created by AI, based on 1 opinions in the last 12 months.
The BMO EqWt US HthCare Hedged CAD, symbol ZUH-T, is perceived positively among experts for its equal-weight strategy that mitigates the risks associated with concentration in mega-pharmaceutical companies. With its focus on pharmaceuticals, biotech, and healthcare services, the fund is considered a strong candidate for those looking to invest in lower volatility sectors. The defensive growth characteristics and steady demand in healthcare contribute to a robust outlook, coupled with strong balance sheets and low economic sensitivity. Additionally, the potential for significant healthcare innovation driven by artificial intelligence is anticipated to provide a substantial boost to this sector. Although the expert does not directly own the ETF, they acknowledge its merits and use alternative methods to gain similar exposure for clients.
They use a covered call strategy to enhance the yield. Those who want exposure to healthcare space but want higher yield, it is a good option. If yield is not a concern for you, you're better off with ZUH.
Billy Kawasaki’s Insights - Picks from 5i Research. Healthcare is likely to be a strong performer in the next five years. Subsectors like medical devices, telemedicine and therapeutics should lead. A good ETF for US exposure. Unlock Premium - Try 5i Free
He does not own this one. They have an effective covered call strategy and has no issues with the fund at all. He prefers ZUH, where it is not impeded with calls being written.
60 names, equally weighted. Prefers names like JNJ, Bristol Myers, UNH, or Merck. His ETF strategy is VHT in US dollars, with more exposure to larger names. Healthcare will be choppy, but it's cheap. Demographics are in its favour.
BMO EqWt US HthCare Hedged CAD is a Canadian stock, trading under the symbol ZUH.TO (previously ZUH-T on Stockchase) on the Toronto Stock Exchange (ZUH-CT). It is usually referred to as TSX:ZUH or ZUH.TO
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on ZUH.TO (previously ZUH-T on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for BMO EqWt US HthCare Hedged CAD.
BMO EqWt US HthCare Hedged CAD was recommended as a Top Pick by Mike Philbrick on 2025-11-27. Read the latest stock experts ratings for BMO EqWt US HthCare Hedged CAD.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for BMO EqWt US HthCare Hedged CAD.
BMO EqWt US HthCare Hedged CAD is followed by 76 investors on Stockchase and is a trending stock that is worth watching.
On 2026-09-09, BMO EqWt US HthCare Hedged CAD (ZUH.TO) stock closed at a price of $77.30.
Equal weight avoids concentration in mega-pharma. Pharma, biotech, healthcare services. Lower volatility sector, so it helps diversify against the narrow leadership in the indexes right now. Defensive growth, steady demand in the area, strong balance sheets, low economic sensitivity. Good valuations.
Kicker is lots of healthcare innovation coming due to AI, and this will be a huge benefit.
Disclosure: Owns this for clients via the futures market. Though he may own similar exposure at times, he doesn't own the individual ETF. His team creates the exposure in a different way.